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Background
Engineering the antigen receptor gene in patients’ lympho-
cytes is one promising strategy to create antigen-specific
lymphocytes without senescent phenotypes. The strategy
provides an opportunity to extend the application of adop-
tive T cell therapy for cancer patients. However, this con-
cept has not been tested in the epithelial cancer patients.
Materials and methods
MAGE-A4-specific TCR a and b chains were cloned
from a human T cell clone that recognises MAGE-
A4143-151 peptide in a HLA-A*24:02 restricted manner.
This T cell clone did not show any cross reactivity to
the peptides with homology to the MAGE-A4143-151 epi-
tope. A retroviral vector that encodes these TCR chains
without any artificial modification was constructed; the
lymphocytes transduced with the retroviral vector killed
the MAGE-A4 expressing tumor in vitro and inhibited
the tumour growth in the NOG immunodeficient mice.
A phase I clinical trial of TCR gene therapy targeting
MAGE-A4 was performed to treat refractory esophageal
cancer patients without lympho-depleting pre-condition-
ing. The trial was designed as a cell-dose escalation consist-
ing of three cohorts, 2x108, 1x109 and 5x109 cells/patient.
Vaccines with the cognate peptide were also given follow-
ing adoptive transfer of lymphocytes on day 14 and day 28.
Results
The treatment was tolerable with no adverse events asso-
ciated with transferred cells or any viral toxicity. In all
ten patients of the 3 cell-doses, the transferred
lymphocytes were detected in their peripheral blood in a
dose-dependent manner during the first 14 days. In 4
patients, the infused cells have been persisting more than
5 months after the transfer. The transferred lymphocytes
that were harvested from the patients more than 50 days
after the transfer were found to sustain the reactivity to
the antigen-expressing tumour cells. Three patients
showed SD or long tumour free status.
Conclusions
This approach may extend the availability of adoptive
T cell therapy for epithelial cancer patients by providing
tumour-reactive and long surviving lymphocytes.
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